Dermatology

Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

This Month in Review summary includes a list of some of the most impactful news in the dermatology space from June 2025.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

This 4-year data highlights dupilumab’s efficacy among children under the age of 12 with atopic dermatitis.

At SDPA 2025, Theodore Rosen, MD, discussed various psychological disorders, including delusions of parasitosis, excoriation disorder, dermatitis artefacta, and others.

Maria Hordinsky, MD, spoke at SDPA regarding her talk highlighting a variety of clinical pearls for spotting scarring alopecia early.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

In her SDPA interview, Maria Hordinsky, MD, spoke about her session regarding clinical pearls for clinicians seeking to spot alopecia early in patients.

At SDPA 2025, Spizuoco discussed how trichoscopic signs like black dots, yellow dots, and exclamation hairs guide treatment decisions.

This interview segment with Scherer highlights additional takeaways from his SDPA 2025 talk, covering clues for clinicians to identify different interdigital foot infections.

In this interview at SDPA, Scherer provides an overview of foot web space infections, fungal versus bacterial infections, and more.

At SDPA 2025, Cotter highlights clinical patterns in alopecia areata that may respond better, or worse, to JAK inhibition and shares his approach to systemic therapy.

This presentation, covered at SDPA, features a discussion by Ginette Okoye, MD, who highlights diagnostic challenges among even experienced clinicians.

At SDPA 2025, Mangin emphasized the importance of wood lamp use, JAK inhibitors, and phototherapy in managing vitiligo and preventing relapse.

Hope Cook, PA-C, speaks in this interview at SDPA about strategies for clinicians seeking to overcome burnout in their careers.

At SDPA 2025, Mangin discussed her vitiligo approach, misconceptions, and how to determine when the disease is active.

In this interview at SDPA 2025, Hope Cook, PA-C, describes the contents of her talk regarding helping clinicians heal from burnout.

Silverberg discussers 16-week data for rezpegaldesleukin in atopic dermatitis from the phase 2b REZOLVE-AD trial.

Silverberg discusses the significance of the dupilumab approval in BP and why he thinks it's the most important news in dermatology in 2025 so far.

In this segment of her SDPA interview, Orit Markowitz, MD, highlights several points about dermoscopy, including common issues with identifying benign lesions.

More than 60% of patients with psoriasis achieved PASI 100 at week 16 with bimekizumab and maintained skin clearance up to 4 Years.

The topics of different hair textures and the management of alopecia in patients with skin of color were highlighted by Ginette Okoye, MD, at SDPA 2025.